Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(3):172-187; doi:10.1093/jnci/dji023
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (80)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Miller, J. C.
Right arrow Articles by Thrall, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, J. C.
Right arrow Articles by Thrall, J. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

REVIEW

Imaging Angiogenesis: Applications and Potential for Drug Development

Janet C. Miller, Homer H. Pien, Dushyant Sahani, A. Gregory Sorensen, James H. Thrall

Affiliation of authors: Center for Biomarkers in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA

Correspondence to: Janet Cochrane Miller, DPhil, Department of Radiology, Massachusetts General Hospital, 100 Charles River Plaza, Boston, MA 02114 (e-mail: jcmiller{at}partners.org).

Recognition of the importance of angiogenesis to tumor growth and metastasis has led to efforts to develop new drugs that are targeted to angiogenic vasculature. Clinical trials of these agents are challenging, both because there is no agreed upon method of establishing the correct dosage for drugs whose mechanism of action is not primarily cytotoxic and because of the long time it takes to determine whether such drugs have a clinical effect. Therefore, there is a need for rapid and effective biomarkers to establish drug dosage and monitor clinical response. This review addresses the potential of imaging as a way to accurately and reliably assess changes in angiogenic vasculature in response to therapy. We describe the advantages and disadvantages of several imaging modalities, including positron emission tomography, x-ray computed tomography, magnetic resonance imaging, ultrasound, and optical imaging, for imaging angiogenic vasculature. We also discuss the analytic methods used to derive blood flow, blood volume, empirical semiquantitative hemodynamic parameters, and quantitative hemodynamic parameters from pharmacokinetic modeling. We examine the validity of these methods, citing studies that test correlations between data derived from imaging and data derived from other established methods, their reproducibility, and correlations between imaging-derived hemodynamic parameters and other pathologic indicators, such as microvessel density, pathology score, and disease outcome. Finally, we discuss which imaging methods are most likely to have the sensitivity and reliability required for monitoring responses to cancer therapy and describe ways in which imaging has been used in clinical trials to date.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Matsumoto, H. Yasui, S. Batra, Y. Kinoshita, M. Bernardo, J. P. Munasinghe, H. Utsumi, R. Choudhuri, N. Devasahayam, S. Subramanian, et al.
Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI
PNAS, October 20, 2009; 106(42): 17898 - 17903.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C.-I. Wong, T.-S. Koh, R. Soo, S. Hartono, C.-H. Thng, E. McKeegan, W.-P. Yong, C.-S. Chen, S.-C. Lee, J. Wong, et al.
Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies
J. Clin. Oncol., October 1, 2009; 27(28): 4718 - 4726.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. Iwasaki and S.-i. Nihira
Anti-angiogenic Therapy Against Gastrointestinal Tract Cancers
Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 543 - 551.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. H. Lee, E. L. Rosen, and D. A. Mankoff
The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions
J. Nucl. Med., May 1, 2009; 50(5): 738 - 748.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. T.-F. Shih, H.-A. Hou, C.-Y. Liu, B.-B. Chen, J.-L. Tang, H.-Y. Chen, S.-Y. Wei, M. Yao, S.-Y. Huang, W.-C. Chou, et al.
Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival
Blood, April 2, 2009; 113(14): 3161 - 3167.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
S. Makkat, R. Luypaert, T. Stadnik, C. Bourgain, S. Sourbron, M. Dujardin, J. De Greve, and J. De Mey
Deconvolution-based Dynamic Contrast-enhanced MR Imaging of Breast Tumors: Correlation of Tumor Blood Flow with Human Epidermal Growth Factor Receptor 2 Status and Clinicopathologic Findings--Preliminary Results
Radiology, November 1, 2008; 249(2): 471 - 482.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. M. Kenny, R. C. Coombes, I. Oulie, K. B. Contractor, M. Miller, T. J. Spinks, B. McParland, P. S. Cohen, A.-M. Hui, C. Palmieri, et al.
Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients
J. Nucl. Med., June 1, 2008; 49(6): 879 - 886.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
N. A. Mullani, R. S. Herbst, R. G. O'Neil, K. L. Gould, B. J. Barron, and J. L. Abbruzzese
Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow
J. Nucl. Med., April 1, 2008; 49(4): 517 - 523.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Sarker, R. Molife, T.R. J. Evans, M. Hardie, C. Marriott, P. Butzberger-Zimmerli, R. Morrison, J. A. Fox, C. Heise, S. Louie, et al.
A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Clin. Cancer Res., April 1, 2008; 14(7): 2075 - 2081.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll Cardiol ImgHome page
T. T. Rissanen, P. Korpisalo, H. Karvinen, T. Liimatainen, S. Laidinen, O. H. Grohn, and S. Yla-Herttuala
High-resolution ultrasound perfusion imaging of therapeutic angiogenesis.
J. Am. Coll. Cardiol. Img., January 1, 2008; 1(1): 83 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Palmowski, J. Huppert, G. Ladewig, P. Hauff, M. Reinhardt, M. M. Mueller, E. C. Woenne, J. W. Jenne, M. Maurer, G. W. Kauffmann, et al.
Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects
Mol. Cancer Ther., January 1, 2008; 7(1): 101 - 109.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Chen, S. Delaloye, D. H.S. Silverman, C. Geist, J. Czernin, J. Sayre, N. Satyamurthy, W. Pope, A. Lai, M. E. Phelps, et al.
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
J. Clin. Oncol., October 20, 2007; 25(30): 4714 - 4721.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
A. Thukral, D. M. Thomasson, C. K. Chow, R. Eulate, S. B. Wedam, S. N. Gupta, B. J. Wise, S. M. Steinberg, D. J. Liewehr, P. L. Choyke, et al.
Inflammatory Breast Cancer: Dynamic Contrast-enhanced MR in Patients Receiving Bevacizumab Initial Experience
Radiology, September 1, 2007; 244(3): 727 - 735.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
L. Mileshkin, D. Honemann, P. Gambell, M. Trivett, Y. Hayakawa, M. Smyth, V. Beshay, D. Ritchie, P. Simmons, A. D. Milner, et al.
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome
Haematologica, August 1, 2007; 92(8): 1075 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H.-J. Wester
Nuclear Imaging Probes: from Bench to Bedside
Clin. Cancer Res., June 15, 2007; 13(12): 3470 - 3481.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Peddinti, R. Zeine, D. Luca, R. Seshadri, A. Chlenski, K. Cole, B. Pawel, H. R. Salwen, J. M. Maris, and S. L. Cohn
Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma
Clin. Cancer Res., June 15, 2007; 13(12): 3499 - 3506.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. W. Xuan, M. Bygrave, H. Jiang, F. Valiyeva, J. Dunmore-Buyze, D. W. Holdsworth, J. I. Izawa, G. Bauman, M. Moussa, S. F. Winter, et al.
Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound
Cancer Res., March 15, 2007; 67(6): 2830 - 2839.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
X. Montet, J.-L. Figueiredo, H. Alencar, V. Ntziachristos, U. Mahmood, and R. Weissleder
Tomographic Fluorescence Imaging of Tumor Vascular Volume in Mice
Radiology, March 1, 2007; 242(3): 751 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
J. M. Provenzale
Imaging of Angiogenesis: Clinical Techniques and Novel Imaging Methods
Am. J. Roentgenol., January 1, 2007; 188(1): 11 - 23.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
J. D. Berry and G. J. R. Cook
Positron emission tomography in oncology
Br. Med. Bull., December 14, 2006; (2006) ldl013v1.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Nakamura, E. Taguchi, T. Miura, A. Yamamoto, K. Takahashi, F. Bichat, N. Guilbaud, K. Hasegawa, K. Kubo, Y. Fujiwara, et al.
KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties.
Cancer Res., September 15, 2006; 66(18): 9134 - 9142.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Dome, J. Timar, J. Dobos, L. Meszaros, E. Raso, S. Paku, I. Kenessey, G. Ostoros, M. Magyar, A. Ladanyi, et al.
Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer.
Cancer Res., July 15, 2006; 66(14): 7341 - 7347.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Hylton
Dynamic Contrast-Enhanced Magnetic Resonance Imaging As an Imaging Biomarker
J. Clin. Oncol., July 10, 2006; 24(20): 3293 - 3298.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Moffat, M. Chen, M. S.T. Kariaapper, D. A. Hamstra, D. E. Hall, J. Stojanovska, T. D. Johnson, M. Blaivas, M. Kumar, T. L. Chenevert, et al.
Inhibition of Vascular Endothelial Growth Factor (VEGF)-A Causes a Paradoxical Increase in Tumor Blood Flow and Up-Regulation of VEGF-D
Clin. Cancer Res., March 1, 2006; 12(5): 1525 - 1532.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, K. A. Krohn, S. M. Larson, R. Weissleder, D. A. Mankoff, J. M. Hoffman, J. M. Link, K. Z. Guyton, W. C. Eckelman, H. I. Scher, et al.
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
Clin. Cancer Res., November 15, 2005; 11(22): 7967 - 7985.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
C M L West and N Charnley
The potential of PET to increase understanding of the biological basis of tumour and normal tissue response to radiotherapy
Br. J. Radiol., November 1, 2005; Supplement_28(1): 50 - 54.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.